On May 5, 2020, Organicell Regenerative Medicine announced the FDA has approved the Investigational New Drug application for its lead product, Organicell Flow, for patients diagnosed with moderate to severe acute respiratory syndrome due to COVID-19 infection.

This trial will be the first randomized, double-blinded, placebo-controlled, phase I/II multi-center clinical trial investigating the safety and potential efficacy of amniotic fluid sourced components for COVID-19.